Results 11 to 20 of about 19,263 (243)

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma [PDF]

, 2017
New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first-in-class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM ...
Ahmadi, Tahamtan, Clemens, Pamela L, Jansson, Richard, Khan, Imran, Liu, Kevin, Lokhorst, Henk M, Lonial, Sagar, Perez Ruixo, Juan Jose, Plesner, Torben, Puchalski, Thomas, Voorhees, Peter M, Xu, Xu Steven, Yan, Xiaoyu, Zhou, Honghui   +13 more
core   +3 more sources

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors [PDF]

OncoImmunology, 2019
Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity
Wojciech Dawicki, Kevin J.H. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova   +7 more
doaj   +2 more sources

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies [PDF]

Haematologica, 2020
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Maria-Victoria Mateos, Andrew Spencer, Ajay K. Nooka, Ludek Pour, Katja Weisel, Michele Cavo, Jacob P. Laubach, Gordon Cook, Shinsuke Iida, Lotfi Benboubker, Saad Z. Usmani, Sung-Soo Yoon, Nizar J. Bahlis, Christopher Chiu, Jon Ukropec, Jordan M. Schecter, Xiang Qin, Lisa O’Rourke, Meletios A. Dimopoulos   +18 more
doaj   +2 more sources

Scleredema Associated With IgG/κ Monoclonal Gammopathy of Clinical Significance Successfully Treated With Daratumumab Monotherapy: A Case Report. [PDF]

EJHaem
ABSTRACT Background Cutaneous monoclonal gammopathy of clinical significance (MGCS) is rare and may present with scleredema‐like fibrosing skin disease. Case A 59‐year‐old man developed progressive induration of the upper body. Laboratory studies revealed an IgG/κ monoclonal protein, and skin biopsy showed dermal thickening with mucin deposition.
Marcolongo D, Bressan A, Zanatta E, Alaibac MSA, Gianesello I, Binotto G, Pavan L, Tos APD, Trentin L, Vianello F.   +9 more
europepmc   +2 more sources

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model [PDF]

eJHaem, 2023
Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy.
Niels vanNieuwenhuijzen, Marta Cuenca, Leonie Abbink, Margot Jak, Victor Peperzak, Monique C. Minnema   +5 more
doaj   +2 more sources

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

Haematologica, 2020
Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of ...
Jesus San-Miguel, Saad Z. Usmani, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Andrew Farnsworth, Hareth Nahi, Ajai Chari   +16 more
doaj   +1 more source

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Experimental Hematology & Oncology, 2018
Background The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells.
Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga, Raymond L. Comenzo   +13 more
doaj   +1 more source

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation

Therapeutic Advances in Hematology, 2021
Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM). MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy.
Chen-lu Yang, Neng-gang Jiang, Li Zhang, Kai Shen, Yu Wu   +4 more
doaj   +1 more source

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis

Journal of International Medical Research, 2021
Objective To systematically evaluate the efficacy and safety of combination regimens containing daratumumab in patients with multiple myeloma (MM). Methods A systematic search of publications listed on electronic databases (PubMed®, The Cochrane Library,
Yin Wang, Yanqing Li, Ye Chai
doaj   +1 more source

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

Haematologica, 2023
Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis is still challenging, and the prognosis remains very poor. Mayo stage IIIb patients were excluded from the pivotal trial leading to the approval of daratumumab in combination with ...
Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Maria Papathanasiou, Tienush Rassaf, Andreas Thimm, Tim Hagenacker, Eyad Naser, Ulrich Duhrsen, Hans C. Reinhardt, Martin Kortum, Hermine Agis, Stefan Schonland, Alexander Carpinteiro   +14 more
doaj   +1 more source